# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001628280-20-003951
Filing Date
2020-03-23
Accepted
2020-03-23 17:18:46
Documents
7
Period of Report
2020-05-18

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | sgmo-2020_proxyxprelim.htm | PRE 14A | 1533307
2 |  | sgmocdagraphiccashinc01.jpg | GRAPHIC | 99051
3 |  | sgmocdagraphicceo2019a02.jpg | GRAPHIC | 43356
4 |  | sgmocdagraphicfactors.jpg | GRAPHIC | 56944
5 |  | sgmocdagraphicprimarya01.jpg | GRAPHIC | 54098
6 |  | sgmoproxycardp1.jpg | GRAPHIC | 196286
7 |  | sgmoproxycardp2.jpg | GRAPHIC | 95535
| Complete submission text file | 0001628280-20-003951.txt |  | 2264492

Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-30171 | Film No.: 20735700
SIC: 2836 Biological Products, (No Diagnostic Substances)